The global industry was valued at US$ 2.2 Bn in 2023 and is expected to grow at a CAGR of 12.6% from 2024 to 2034, reaching US$ 8.2 Bn by the end of 2034. The hERG screening market is witnessing significant growth due to the increasing focus on drug safety assessment and the rising demand for advanced preclinical testing solutions in the pharmaceutical and biotechnology industries. hERG screening plays a crucial role in evaluating the cardiotoxicity potential of drug candidates by identifying interactions with the human Ether-à-go-go-Related Gene (hERG) potassium channel, which is directly linked to cardiac arrhythmias. As regulatory agencies continue to emphasize stringent drug safety standards, the importance of reliable hERG screening technologies is rapidly increasing across the global healthcare sector.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86227

Market Overview

The hERG screening market has evolved into a vital component of the drug discovery and development process. Pharmaceutical companies are increasingly integrating hERG assays into early-stage research to minimize the risk of late-stage drug failures and regulatory setbacks. The growing complexity of drug development, combined with rising investments in precision medicine and biologics, is driving demand for advanced screening technologies that offer accurate and high-throughput analysis. Additionally, technological advancements in automated electrophysiology, fluorescence-based assays, and in silico modeling are improving the efficiency and reliability of hERG screening procedures. These innovations are helping pharmaceutical and biotech firms accelerate drug development timelines while ensuring patient safety and regulatory compliance.

Market Size and Growth

Valued at US$ 2.2 Bn in 2023, the hERG screening market is projected to reach US$ 8.2 Bn by 2034, expanding at a robust CAGR of 12.6%. This strong growth trajectory is primarily fueled by the increasing number of drug discovery programs worldwide and the growing incidence of cardiovascular disorders, which require safer therapeutic solutions. Rising R&D expenditure by pharmaceutical and biotechnology companies is also contributing significantly to market expansion. Furthermore, the growing adoption of contract research organizations (CROs) for preclinical testing services is creating additional growth opportunities. As regulatory frameworks become more stringent regarding cardiac safety evaluation, demand for advanced hERG screening platforms is expected to continue rising steadily over the forecast period.

Market Segmentation

The hERG screening market can be segmented based on technology, assay type, end-user, and application. By technology, the market includes automated patch clamp systems, manual patch clamp systems, fluorescence-based assays, and computational models, with automated systems gaining popularity due to their speed and scalability. In terms of assay type, the market is categorized into in vitro assays and in silico assays, both playing a critical role in comprehensive cardiotoxicity assessment. End-users include pharmaceutical companies, biotechnology firms, academic research institutes, and CROs, with pharmaceutical companies accounting for a major share due to extensive drug development activities. Increasing demand for cost-effective and high-throughput screening methods is further influencing market dynamics.

Regional Analysis

Regionally, North America dominates the hERG screening market, supported by a strong pharmaceutical industry, advanced healthcare infrastructure, and substantial investments in drug discovery research. The United States remains a major contributor due to the presence of leading pharmaceutical companies and stringent FDA regulations regarding cardiac safety assessment. Europe also holds a significant market share, driven by rising R&D activities and supportive regulatory policies. Meanwhile, Asia-Pacific is expected to witness the fastest growth during the forecast period, fueled by expanding pharmaceutical manufacturing capabilities, increasing clinical research activities, and growing investments in biotechnology in countries such as China, India, and Japan. Emerging markets in Latin America and the Middle East & Africa are also gradually adopting advanced screening technologies.

Competitive Landscape

The hERG screening market is highly competitive, with key players focusing on technological innovation, strategic partnerships, and service expansion to strengthen their market presence. Some of the major companies covered in the market report include Abcam Limited, ABR-Affinity BioReagents, Inc., AstraZeneca plc, Aureus Sciences, AVIVA Biosciences, Cambridge Biosciences, ChanTest Corporation, Charles River Laboratories, and Chemaxon. These companies are investing heavily in research and development to enhance assay accuracy, throughput, and automation capabilities. Collaborations between pharmaceutical firms and screening technology providers are also contributing to market growth by enabling the development of advanced and integrated testing solutions.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453